Friday, June 26, 2015

Celgene fishing for [Kyle] Bass?

In a post titled Celgene May Seek Sanctions Against Kyle Bass Over Patent Challenges , the Wall Street Journal notes of Bass's IPR against claims of Celgene patents (including one patent related to a drug for alleviating problems caused by MS, the patent relating to Tecfidera, a multiple sclerosis drug that had $2.9 billion in sales last year.}:

In response to a patent challenge filed by the hedge-fund manager, Celgene recently won permission from the U.S. Patent and Trademark Office to file a motion seeking sanctions against a Bass entity for allegedly abusing the process for reviewing patents.

Although Celgene has not yet filed a motion, the development is being closely watched because it raises the possibility that patent officials may put an end to a tactic Bass has used to challenge valuable patents held by drug makers and biotechs.


Post a Comment

<< Home